MannKind's FUROSCIX ReadyFlow Autoinjector receives FDA approval for CHF and CKD treatment.

MannKind Corporation's FUROSCIX ReadyFlow Autoinjector, a subcutaneous furosemide injection, has been accepted by the FDA for approval. If approved, it would deliver an IV-equivalent dose in under 10 seconds, providing a cost-effective and convenient option for treating fluid buildup at home. The PDUFA target action date is July 26, 2026.